ArticleDrug design, development and therapy2026
DAPT Mitigates Osteoarthritic Cartilage Degeneration and Enhances Articular Repair Through Targeted Modulation of the Gucy1a3 and Notch Signaling Axis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Notch signaling pathway in joint homeostasis and osteoarthritis.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While Nitric oxide (NO) and Notch signaling pathways are implicated in osteoarthritis (OA) progression, their functional interplay remains largely unexplored. We hypothesized that Gucy1a3 (sGCα1) functions as a non-canonical soluble sensor, bridging nitrosative stress to pathological Notch activation. Methods: To test the hypothesis that Gucy1a3 mediates NO-Notch crosstalk, we used both sodium nitroprusside (SNP)-stimulated chondrocytes and a rat medial meniscus resection model. Mechanistic hierarchy was analyzed via Gucy1a3 siRNA knockdown and the Notch inhibitor DAPT. Additionally, the capacity of DAPT to modulate chondrogenic lineage commitment was evaluated in rat bone marrow mesenchymal stem cells (BMSCs). Results: DAPT reversed SNP-induced catabolism in chondrocytes, suppressing Notch components (Notch1, Jagged1) and inflammatory markers (iNOS, MMP13) while restoring anabolic gene expression. Crucially, DAPT suppressed Gucy1a3 expression, breaking a reciprocal positive feedback loop (NO-Gucy1a3-Notch). Although Gucy1a3 knockdown phenocopied the anti-inflammatory signature of DAPT, DAPT uniquely activated the chondrogenic differentiation of BMSCs. In preclinical models, intra-articular delivery of DAPT effectively safeguarded joint homeostasis by reducing subchondral bone deterioration and decreasing cartilage degeneration. Conclusion: This study identifies Gucy1a3 as a mediator that transduces inflammatory nitric oxide signals to activate Notch. DAPT exerts therapeutic effects by inhibiting Gucy1a3-mediated catabolism in chondrocytes and promoting the differentiation of BMSCs. Although these findings are currently limited to in vitro and rodent models, targeting this signaling axis offers a potential strategy for developing disease-modifying osteoarthritis drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.